Physician profile
Andrew So
NPI 1952794737
$6,365.98
in general payments reported to CMS, 2019-2025
28 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $1,826 · 2021: $634 · 2022: $867 · 2023: $575 · 2024: $844 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,988.97 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic Vascular, INC. | $945.62 | 2020 | |
| Biotronik Nro, INC. | $712.00 | 2023-2025 | Prospera, Biotronik |
| Medtronic, INC. | $615.02 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Closurefast |
| Vertos Medical, INC. | $275.36 | 2022-2024 | Mild Device Kit |
| Medtronic USA, INC. | $245.31 | 2020 | |
| Abbott Laboratories | $212.95 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.11 | 2022-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $187.08 | 2022-2025 | |
| Abbvie INC. | $174.71 | 2022-2025 | Botox |
| Collegium Pharmaceutical, INC. | $139.44 | 2020-2024 | Xtampza |
| Nalu Medical, INC. | $116.03 | 2022-2024 | Nalu Neurostimulation System |
| Nevro Corp. | $86.96 | 2022 | |
| Si-Bone, INC. | $76.61 | 2022 | |
| Janssen Biotech, INC. | $69.04 | 2025 | Tremfya |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $58.73 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Redhill Biopharma INC. | $56.45 | 2020-2021 | |
| Virtus Pharmaceuticals LLC | $39.91 | 2021 | |
| Allergan, INC. | $25.85 | 2019-2021 | |
| Foundation Fusion Solutions, LLC | $21.98 | 2022-2023 | |
| Axonics, INC. | $21.89 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.94 | 2023 | Iovera, Zilretta, Exparel |
| Tersera Therapeutics LLC | $14.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.11 | 2021 | |
| Spr Therapeutics, INC | $14.10 | 2022 | |
| Averitas Pharma INC. | $13.34 | 2023 | Qutenza |
| Ibsa Pharma INC. | $13.05 | 2022 | |
| Saluda Medical Americas, INC. | $12.92 | 2024 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.